Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: A review

Oncologist

Volumn 16, Issue 9, 2011, Pages 1239-1249

  Baas, Jara M ^a   Krens, Lisanne L ^a   Guchelaar, Henk Jan ^a   Morreau, Hans ^a   Gelderblom, Hans ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Colorectal cancer; Concordance; EGFR inhibitors; KRAS; Monoclonal antibodies

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ARTICLE; CODON; COLORECTAL CANCER; DNA ISOLATION; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; METASTASIS POTENTIAL; MUTATIONAL ANALYSIS; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; PREDICTION; PRIMARY TUMOR; PRIORITY JOURNAL; PYROSEQUENCING; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE STRAND CONFORMATION POLYMORPHISM; SYSTEMATIC REVIEW;

ANIMALS; COLORECTAL NEOPLASMS; HUMANS; MUTATION; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 80053198693     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0024     Document Type: Article

References (68)

1. Siena S, Sartore-Bianchi A, Di Nicolantonio F et al. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 2009;101:1308-1324.
2. Rocha-Lima CM, Soares HP, Raez LE et al. EGFR targeting of solid tumors. Cancer Control 2007;14:295-304.
3. Laurent-Puig P, Lievre A, Blons H. Mutations and response to epidermal growth factor receptor inhibitors. Clin Cancer Res 2009;15:1133-1139.
4. Jonker DJ, O'Callaghan CJ, Karapetis CS, etal. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040-2048.
5. van Cutsem E, Peeters M, Siena S et al. Open-label phase III trial of pani-tumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658-1664.
6. Khambata-Ford S, Garrett CR, Meropol NJ et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in met-astatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007;25:3230-3237.
7. Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for pa-nitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-1634.
8. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximabin advanced colorectal cancer. N EnglJ Med 2008;359: 1757-1765.
9. de Roock W, Jonker DJ, Di Nicolantonio F et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010;304: 1812-1820.
10. Albitar M, Yeh C, Ma W. K-ras mutations and cetuximab in colorectal cancer. N Engl J Med 2009;360:834; author reply 835-836.
11. Bokemeyer C, Bondarenko I, Makhson A et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27:663-671.
12. Hecht JR, Mitchell E, Chidiac T et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009; 27:672-680.
13. Prenen H, de Schutter J, Jacobs B et al. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res 2009;15:3184-3188.
14. Tol J, Koopman M, Cats A et al. Chemotherapy, bevacizumab, and cetux-imab in metastatic colorectal cancer. N Engl J Med 2009;360:563-572.
15. van Cutsem E, Köhne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360: 1408-1417.
16. de Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis. Lancet Oncol 2010;11:753-762.
17. Brink M, de Goeij AF, Weijenberg MP et al. K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogen-esis 2003;24:703-710.
18. Frattini M, Balestra D, Suardi S et al. Different genetic features associated with colon and rectal carcinogenesis. Clin Cancer Res 2004;10:4015-4021.
19. Edkins S, O'Meara S, Parker A, et al. Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biol Ther 2006;5:928-932.
20. Loupakis F, Ruzzo A, Cremolini C et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009;101: 715-721.
21. van Krieken JH, Jung A, Kirchner T et al. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: Proposal foranEuropean quality assurance program. Virchows Arch 2008;453:417-431.
22. DiNicolantonio F, Martini M, Molinari F, et al. Wild-type BRAFisrequired for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008;26:5705-5712.
23. Souglakos J, Philips J, Wang R et al. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer 2009;101:465-472.
24. Tol J, Nagtegaal ID, Punt CJ. BRAF mutation in metastatic colorectal cancer. N Engl J Med 2009;361:98-99.
25. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of meta-static colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007;67:2643-2648.
26. Cappuzzo F, Varella-Garcia M, Finocchiaro G et al. Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. Br J Cancer 2008;99:83-89.
27. de Roock W, Lambrechts D, Tejpar S. K-ras mutations and cetuximab in colorectal cancer. N Engl J Med 2009;360:834; author reply 835-836.
28. Molinari F, Martin V, Saletti P et al. Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant. Br J Cancer 2009;100:1087-1094.
29. Banck MS, Grothey A. Biomarkers ofresistance toepidermal growth factor receptor monoclonal antibodies in patients with metastatic colorectal cancer. Clin Cancer Res 2009;15:7492-7501.
30. Loupakis F, Pollina L, Stasi I et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetux-imab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 2009;27:2622-2629.
31. Perrone F, Lampis A, Orsenigo M et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 2009;20:84-90.
32. Sartore-Bianchi A, Martini M, Molinari F et al. PIK3CA mutations in colo-rectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 2009;69:1851-1857.
33. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-767.
34. Belly R, Rosenblatt J, Steinmann M et al. K-12 Ras mutations in lymph nodes are a prognostic indicator in Dukes' B colorectal cancer. Proc Am Soc Clin Oncol 2000;19:Abstract 2632B.
35. Clarke GA, Ryan E, Crowe JP et al. Tumour-derived mutated K-ras codon 12 expression in regional lymph nodes of stage II colorectal cancer patients is not associated with increased risk of cancer-related death. Int J Colorectal Dis 2001;16:108-111.
36. Tórtola S, Steinert R, Hantschick M et al. Discordance between K-ras mutations in bone marrow micrometastases and the primary tumor in colorec-tal cancer. J Clin Oncol 2001;19:2837-2843.
37. Oliveira C, Velho S, Moutinho C et al. KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. Oncogene 2007;26:158-163.
38. Jones S, Chen WD, Parmigiani G et al. Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A 2008;105: 4283-4288.
39. Etienne-Grimaldi MC, Formento JL, Francoual M et al. K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer Res 2008;14:4830-4835.
40. Finkelstein SD, Sayegh R, Christensen S et al. Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation type. Cancer 1993;71:3827-3838.
41. Losi L, Benhattar J, Costa J. Stability of K-ras mutations throughout the natural history of human colorectal cancer. Eur J Cancer 1992;28A:1115-1120.
42. Suchy B, Zietz C, Rabes HM. K-ras point mutations in human colorectal carcinomas: Relation to aneuploidy and metastasis. Int J Cancer 1992;52: 30-33.
43. Zauber P, Sabbath-Solitare M, Marotta SP et al. Molecular changes in the Ki-ras and APC genes in primary colorectal carcinoma and synchronous metastases compared with the findings in accompanying adenomas. Mol Pathol 2003;56:137-140.
44. Artale S, Sartore-Bianchi A, Veronese SM et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 2008;26:4217-4219.
45. Cejas P, López-Gómez M, Aguayo C et al. KRAS mutations in primary colorectal cancer tumors and related metastases: A potential role in prediction of lung metastasis. PLoS One 2009;4:e8199.
46. Garm Spindler KL, Pallisgaard N, Rasmussen AA et al. The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetux-imab and irinotecan in metastatic colorectal cancer. Ann Oncol 2009;20: 879-884.
47. Italiano A, Hostein I, Soubeyran I et al. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: Biological and clinical implications. Ann Surg Oncol 2010;17:1429-1434.
48. Knijn N, Mekenkamp LJ, Klomp M et al. KRAS mutation analysis: A comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer 2011;104:1020-1026.
49. Melucci E, Conti S, Diodoro M et al. Relationship between K-Ras mutational status and EGFR expression evaluated using Allred score in primary and metastatic colorectal cancer. J Clin Oncol 2010;28(15 suppl):3568.
50. Santini D, Loupakis F, Vincenzi B, et al. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: Implications for clinical practice. The Oncologist 2008;13:1270-1275.
51. Schimanski CC, Linnemann U, Berger MR. Sensitive detection of K-ras mutations augments diagnosis of colorectal cancer metastases in the liver. Cancer Res 1999;59:5169-5175.
52. Al-Mulla F, Going JJ, Sowden ET et al. Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortality. J Pathol 1998;185:130-138.
53. Albanese I, Scibetta AG, Migliavacca M et al. Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations. Biochem Biophys Res Commun 2004;325:784-791.
54. Baldus SE, Schaefer KL, Engers R et al. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 2010;16:790-799.
55. Thebo JS, Senagore AJ, Reinhold DS et al. Molecular staging of colorectal cancer: K-ras mutation analysis of lymph nodes upstages Dukes B patients. Dis Colon Rectum 2000;43:155-159; discussion 159-162.
56. Oudejans JJ, Slebos RJ, Zoetmulder FA et al. Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver. Int J Cancer 1991;49:875-879.
57. Cejas P, Lopes-Gomez M, Aguayo C et al. Analysis of EGFR pathway mediators in KRAS wild-type primary tumors is not representative of their status in related metastases. J Clin Oncol 2010;28(15 suppl):3589.
58. Santini D, Spoto C, Loupakis F et al. High concordance of BRAF status between primary colorectal tumours and related metastatic sites: Implications for clinical practice. Ann Oncol 2010;21:1565.
59. Negri FV, Bozzetti C, Lagrasta CA et al. PTEN status in advanced colorectal cancer treated with cetuximab. Br J Cancer 2010;102:162-164.
60. Sood A, McClain D, Seetharam R et al. Beyond KRAS: The quest for novel genetic markers predictive for response to anti-epidermal growth factor receptor (EGFR) therapy in patients with metastatic colorectal cancer (mCRC). J Clin Oncol 2010;28(15 suppl):3567.
61. Bos JL, Fearon ER, Hamilton SR et al. Prevalence of ras gene mutations in human colorectal cancers. Nature 1987;327:293-297.
62. Vogelstein B, Fearon ER, Hamilton SR et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-532.
63. Plesec TP, Hunt JL. KRAS mutation testing in colorectal cancer. Adv Anat Pathol 2009;16:196-203.
64. Oliner K, Juan T, Suggs S et al. A comparability study of 5 commercial KRAS tests. Diagn Pathol 2010;5:23-30.
65. Shibata D, Schaeffer J, Li ZH et al. Genetic heterogeneity of the c-K-ras locus in colorectal adenomas but not in adenocarcinomas. J Natl Cancer Inst 1993;85:1058-1063.
66. Di Fiore F, Blanchard F, Charbonnier F et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 2007;96:1166-1169.
67. Ishii M, Sugai T, Habano W et al. Analysis of Ki-ras gene mutations within the same tumor using a single tumor crypt in colorectal carcinomas. J Gas-troenterol 2004;39:544-549.
68. Cejas P, Lopes-Gomez M, Madero R et al. Concordance of K-Ras status between colorectal cancer (CRC) primaries and related metastatic samples considering clinicopathological features. J Clin Oncol 2009;27(15 suppl): 4053.